证券代码：002932 证券简称：明德生物 公告编号：2026-003 武汉明德生物科技股份有限公司 关于增资并收购蓝怡（湖南）医疗器械有限公司股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）与交易对手方签 署《关于蓝怡（湖南）医疗器械有限公司之收购协议》（以下简称《收购协议》）， 拟于首期收购中以增资及股权收购方式先行取得蓝怡（湖南）医疗器械有限公司 （以下简称"湖南蓝怡"或"标的公司"或"目标公司"）51%股权，首期收购 后湖南蓝怡成为公司控股子公司，纳入公司合并报表范围。若湖南蓝怡于 2026 年度至 2028 年度相关经营情况满足《收购协议》约定的相关前置条件，公司将 根据协议约定进一步收购湖南蓝怡剩余股权（以下简称"二期收购"），前述两 阶段收购完成后，公司将合计持有湖南蓝怡 100%股权。 2、本次交易定价系根据评估机构出具的评估报告（银信评字（2026）第 B00006 号）并考量标的公司的技术实力、行业前景、战略价值等因素后，由交 易各方按照市场化原则谈判后最终确定。经 ...

二、董事会会议审议情况 证券代码：002932 证券简称：明德生物 公告编号：2026-002 武汉明德生物科技股份有限公司 第五届董事会第三次会议决议公告 1、审议通过《关于增资并收购蓝怡（湖南）医疗器械有限公司股权的议案》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉明德生物科技股份有限公司（以下简称"公司"）第五届董事会第三次 会议于 2026 年 1 月 19 日以现场及通讯相结合的方式在公司会议室召开，会议通 知已于 2026 年 1 月 15 日以电子邮件、电话通讯等形式发出。本次会议应到董事 8 名，实际出席会议的董事 8 名，会议由董事长陈莉莉女士主持会议，公司高级 管理人员列席了本次会议，会议的召集和召开符合《中华人民共和国公司法》等 法律法规及《公司章程》的规定。 1、经与会董事签字并加盖董事会印章的第五届董事会第三次会议决议。 特此公告。 武汉明德生物科技股份有限公司 董 事 会 2026 年 1 月 20 日 表决结果：同意票数为 8 票，反对票数为 0 票，弃权票数为 0 票。 同意公司于首期收购中以现 ...

武汉明德生物科技股份有限公司（以下简称"公司"）于2025年4月24日召开 第四届董事会第十九次会议、2025年5月16日召开的2024年年度股东大会审议通 过了《关于续聘2025年度审计机构的议案》。公司同意续聘立信会计师事务所（特 殊普通合伙）（以下简称"立信"）为公司2025年度审计机构。具体内容详见2025 年4月25日及2025年5月17日于指定媒体披露的相关公告。 证券代码：002932 证券简称：明德生物 公告编号：2026-001 武汉明德生物科技股份有限公司 关于变更签字会计师的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三、其他说明 本次变更过程中相关工作安排将有序交接，变更事项不会对公司2025年年度 财务报表和内部控制审计工作产生影响。 四、备查文件 2026年1月12日，公司收到立信出具的《关于变更武汉明德生物科技股份有 限公司签字会计师的函》，立信为公司2025年度财务报表及内部控制的审计机构， 原指派李洪勇先生及刘小华女士作为签字注册会计师为公司提供审计服务。因工 作安排原因，立信现指派刘璐女士接替刘小华女士继续完成公司 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

蓝帆医疗拟出售全资子公司武汉必凯尔救助用品有限公司100%股权，交易对方为深交所主板上市公司 明德生物（002932.SZ）。本次交易旨在聚焦核心主业、增厚现金储备、盘活存量资产、缩短管理半 径。目前尚未签署具有约束力的协议，交易需履行审批程序，存在不确定性。交易不构成关联交易，也 不构成重大资产重组。武汉必凯尔主营业务为急救包及应急救护相关产品和服务。交易完成后，该公司 将不再纳入合并报表范围。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 12月31日主力资金净流入230.4万元，占总成交额3.77%；游资资金净流入67.1万元，占总成交额1.1%； 散户资金净流出297.5万元，占总成交额4.86%。 公司公告汇总关于拟转让全资子公司100%股权的提示性公告 截至2025年12月31日收盘，蓝帆医疗(002382)报收于5.6元，上涨1.63%，换手率1.09%，成交量10.94万 手，成交额6119.24万元。 当日关注点 交易信息汇总资金流向 来自交易信息汇总：12月31日主力资金净流入230.4万元，占总成交额3.77 ...

Group 1 - The core point of the article is that Bluestar Medical (002382) plans to sell its wholly-owned subsidiary, Wuhan Bikaier Rescue Supplies Co., Ltd., to focus on its core business and enhance cash reserves [1] - The transaction is expected to involve cash consideration and aims to activate existing assets while shortening management radius [1] - The buyer of the subsidiary is Wuhan Mingde Biological Technology Co., Ltd. (002932.SZ), which is a listed company on the Shenzhen Stock Exchange and is not considered a related party to Bluestar Medical [1]

Market Overview - The Shanghai Composite Index closed at 3968.84 points, above the annual line, with a slight increase of 0.09% [1] - The total trading volume of A-shares reached 24,617.43 billion yuan [1] Stocks Breaking Annual Line - A total of 92 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Wajingke (8.82%) - Zhangyue Technology (8.44%) - Suoling Co., Ltd. (7.81%) [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Wajingke: 20.00% increase, turnover rate of 14.94%, latest price at 37.80 yuan [1] - Zhangyue Technology: 10.00% increase, turnover rate of 12.20%, latest price at 22.12 yuan [1] - Suoling Co., Ltd.: 10.00% increase, turnover rate of 10.69%, latest price at 6.05 yuan [1] - Other stocks with significant increases include: - Desheng Technology: 10.03% increase - Nanxing Co., Ltd.: 10.00% increase [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Guifaxiang - Guangkang Biochemical - Shunwang Technology [1]

Core Viewpoint - Bluefan Medical plans to sell its emergency rescue business, Wuhang Bikaier Rescue Supplies Co., to Wuhan Mingde Biotechnology Co., aiming to focus on core operations, enhance cash reserves, and optimize asset structure [1][2] Group 1: Strategic Focus and Asset Optimization - The sale of Bikaier represents a significant step in Bluefan Medical's strategy to concentrate on its main business and continuously optimize asset allocation [2] - Bikaier has been a key player in the emergency rescue field, but its value has been difficult to realize within Bluefan due to management radius and resource allocation constraints [2] - The divestment allows Bluefan to streamline operations, reduce complexity, and enhance core competitiveness while addressing concerns about diversified operations [2] Group 2: Financial Structure and Debt Management - The asset disposal is a crucial move for Bluefan to optimize its financial structure and alleviate debt pressure, enhancing liquidity and providing a solid foundation for long-term development [4] - The cash flow generated from the transaction will significantly bolster the company's cash reserves, supporting short-term debt risk mitigation [4] - Increased cash reserves will also facilitate investments in core businesses such as cardiovascular health and health protection, driving long-term high-quality growth [4] Group 3: Potential for Future Growth - Bluefan Medical's stake in Tongxin Medical, which has recently been accepted for an IPO application, could further enhance liquidity and asset value post-listing [3] - The successful listing of Tongxin Medical is expected to significantly increase the value of Bluefan's investment, contributing positively to its financial performance [3] Group 4: Synergies with Mingde Biotechnology - Mingde Biotechnology, located in Wuhan like Bikaier, can quickly integrate Bikaier's established product matrix and customer base, enhancing its market position in critical care [5] - The acquisition will enable Mingde to extend its integrated critical care services into industrial and home settings, creating a collaborative ecosystem [5] Group 5: Mutual Benefits and Collaborative Development - The transaction is set to achieve mutual benefits for both Bluefan Medical and Mingde Biotechnology, leveraging their respective resources for collaborative growth and value creation [6]

中国经济网北京12月31日讯 明德生物(002932.SZ)昨日晚间发布关于筹划重大资产重组暨签署《股 权收购意向协议》的提示性公告。 明德生物与蓝帆医疗股份有限公司（以下简称"交易对方"或"蓝帆医疗"）签署《股权收购意向协 议》，双方就公司以现金方式收购武汉必凯尔救助用品有限公司（以下简称"标的公司"）100%股权的 交易达成框架性意向，并明确双方后续就本次交易进行收购工作安排以及签署正式收购协议等事项。 截至2025年9月末，明德生物的货币资金余额为1.84亿元，较年初减少63%。 截至2025年9月末，明德生物的流动负债合计2.97亿元，年初为4.96亿元。 (责任编辑：田云绯) 本次交易尚处于筹划阶段，此次签署《股权收购意向协议》系各方合作意愿的意向性约定，公司正 在与交易对方就本次交易进行积极洽谈和协商，最终的交易条款以双方签署的正式收购协议为准。 目前本次交易尚存在较大不确定性，因中介机构的尽职调查结果、双方对于交易条件和收购协议的 谈判结果、公司履行的相关审批备案程序结果、本次收购标的公司的实施可能性等均存在较大不确定 性，同时，因市场变化、交易双方未能协商一致、相关事项未能通过决策或审批程序等 ...

Core Viewpoint - Mingde Biological (002932) has signed a share acquisition intention agreement with Bluefan Medical (002382) to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. in cash, which is expected to constitute a major asset restructuring without involving a restructuring listing or issuing shares [1] Group 1: Company Overview - Bikaier is one of the earliest companies in China to introduce the international First Aid concept and technology [1] - The core business of Bikaier focuses on first aid kits, and it has expanded its offerings to include emergency equipment, individual emergency products, and emergency services related to rescue [1] Group 2: Transaction Details - The transaction will result in Bikaier becoming a wholly-owned subsidiary of Mingde Biological upon completion [1] - The acquisition is significant as it enhances Mingde Biological's capabilities in the emergency rescue sector [1]